Padcev for Locally advanced or metastatic urothelial carcinoma
Quick answer: Padcev is used for Locally advanced or metastatic urothelial carcinoma as part of a antibody-drug conjugate (nectin-4 directed, mmae payload) treatment regimen. Enfortumab vedotin: anti-Nectin-4 monoclonal antibody conjugated to monomethyl auristatin E (MMAE) which disrupts microtubules in target tumor cells The specific dosing for Locally advanced or metastatic urothelial carcinoma is determined by your prescriber based on individual factors.
Why is Padcev used for Locally advanced or metastatic urothelial carcinoma?
Padcev belongs to the Antibody-drug conjugate (Nectin-4 directed, MMAE payload) class. Enfortumab vedotin: anti-Nectin-4 monoclonal antibody conjugated to monomethyl auristatin E (MMAE) which disrupts microtubules in target tumor cells This action makes it useful for treating or managing Locally advanced or metastatic urothelial carcinoma in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Padcev is the right choice for a specific patient depends on the type and severity of Locally advanced or metastatic urothelial carcinoma, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Locally advanced or metastatic urothelial carcinoma
Common adult dosing range: 1.25 mg/kg IV (max 125 mg) on days 1, 8, 15 of a 28-day cycle. The actual dose for Locally advanced or metastatic urothelial carcinoma depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Padcev medicine page.
What to expect
Padcev treatment for Locally advanced or metastatic urothelial carcinoma typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Locally advanced or metastatic urothelial carcinoma
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Padcev is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Antibody-drug conjugate (Nectin-4 directed, MMAE payload) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Padcev
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Padcev full prescribing information · All Antibody-drug conjugate (Nectin-4 directed, MMAE payload) alternatives
Frequently asked questions
How effective is Padcev for Locally advanced or metastatic urothelial carcinoma?
Effectiveness varies by individual response, dose, and severity. Padcev is one of several treatment options for Locally advanced or metastatic urothelial carcinoma, supported by clinical evidence within the antibody-drug conjugate (nectin-4 directed, mmae payload) class. Discuss expected response with your prescriber.
How long do I need to take Padcev for Locally advanced or metastatic urothelial carcinoma?
Treatment duration depends on the nature of Locally advanced or metastatic urothelial carcinoma — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Padcev when used for Locally advanced or metastatic urothelial carcinoma?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Padcev for Locally advanced or metastatic urothelial carcinoma?
Yes. Multiple medicines and non-drug options exist for Locally advanced or metastatic urothelial carcinoma. Alternatives within the antibody-drug conjugate (nectin-4 directed, mmae payload) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.